All
All

What are you looking for?

All
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

FGF2-STAB as a key component for the cell-cultured meat media

Project goals

1) To receive feedback on the FGF2-STAB technology to be used specifically for the cell-cultured meat industry 2) To design FGF2-STAB with parameters meeting cell-based meat industry regulatory standards 3) To actively build connections to companies aiming to succeed in the cell-cultured meat market 4) To define a clear go-to-market strategy for our FGF2-STAB in the cell-cultured meat market

Keywords

BiotechnologyFibroblast growth factor 2, FGF2Cell-cultured meat mediaCultivated meat

Public support

  • Provider

    Technology Agency of the Czech Republic

  • Programme

  • Call for proposals

    3.VS GAMA 2 (STA02021TP030)

  • Main participants

    Enantis s.r.o.

  • Contest type

    VS - Public tender

  • Contract ID

    TP03020019 - Smlouva o poskytnutí podpory

Alternative language

  • Project name in Czech

    FGF2-STAB jako klíčová komponenta média pro kultivaci masa

  • Annotation in Czech

    1) Získat zpětnou vazbu na využití FGF2-STAB pro trh kultivovaného masa 2) Identifikace parametrů FGF2-STAB splňujících regulatorní standardy požadované pro výrobu kultivovaného masa 3) Vytvořit aktivní vazby na firmy, které se chtějí prosadit na trhu výroby kultivovaného masa 4) Vytvořit jasnou strategii pro vstup našeho FGF2-STAB na trh kultivovaného masa

Scientific branches

  • R&D category

    VV - Exeperimental development

  • OECD FORD - main branch

    20901 - Industrial biotechnology

  • OECD FORD - secondary branch

    30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])

  • OECD FORD - another secondary branch

    40401 - Agricultural biotechnology and food biotechnology

  • EI - Biotechnology and bionics

Completed project evaluation

  • Provider evaluation

    U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

  • Project results evaluation

    The topic of the project and the application of the given protein is very interesting and promising. After solving the fundamental issues, especially of a regulatory, production and financial nature, there is a great potential for a high impact on the company. The recipient has contacted potential partners, has feedback from them and therefore knows what to focus on in the immediate future. The weakness remains the regulatory environment, which is essentially at the beginning in both the EU and the US, but is crucial for the launch of the product itself on the market.

Solution timeline

  • Realization period - beginning

    Oct 1, 2021

  • Realization period - end

    Mar 31, 2022

  • Project status

    U - Finished project

  • Latest support payment

    Feb 28, 2022

Data delivery to CEP

  • Confidentiality

    C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.

  • Data delivery code

    CEP23-TA0-TP-U

  • Data delivery date

    Jun 30, 2023

Finance

  • Total approved costs

    938 thou. CZK

  • Public financial support

    516 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    422 thou. CZK

Basic information

Recognised costs

938 CZK thou.

Public support

516 CZK thou.

55%


Provider

Technology Agency of the Czech Republic

OECD FORD

Industrial biotechnology

Solution period

01. 10. 2021 - 31. 03. 2022